178 related articles for article (PubMed ID: 1374412)
21. [Significance of CA72-4 as a follow up of recurrent gastric cancer--comparison with CEA and CA19-9].
Takahashi Y; Mai M
Gan To Kagaku Ryoho; 1992 Apr; 19(4):515-8. PubMed ID: 1558402
[TBL] [Abstract][Full Text] [Related]
22. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
[TBL] [Abstract][Full Text] [Related]
23. An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4.
Yu J; Zheng W
J Gastrointest Cancer; 2018 Mar; 49(1):57-62. PubMed ID: 28028765
[TBL] [Abstract][Full Text] [Related]
24. Detection of tumor associated antigen, PA8-15, in sera from pancreatic and gastrointestinal carcinoma patients.
Arai M; Sakamoto K; Otsuka H; Yokoyama Y; Akagi M
Jpn J Clin Oncol; 1990 Jun; 20(2):145-53. PubMed ID: 2370693
[TBL] [Abstract][Full Text] [Related]
25. Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity.
Pan Q; Law COK; Yung MMH; Han KC; Pon YL; Lau TCK
PLoS One; 2018; 13(10):e0198980. PubMed ID: 30303958
[TBL] [Abstract][Full Text] [Related]
26. Detection of carcinoembryonic antigen and related antigens in sera of patients with gastrointestinal tumors using monoclonal antibodies in double-determinant radioimmunoassays.
Herlyn M; Blaszczyk M; Sears HF; Verrill H; Lindgren J; Colcher D; Steplewski Z; Schlom J; Koprowski H
Hybridoma; 1983; 2(3):329-39. PubMed ID: 6205981
[TBL] [Abstract][Full Text] [Related]
27. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
[TBL] [Abstract][Full Text] [Related]
28. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies.
Lopez JB; Royan GP; Lakhwani MN; Mahadaven M; Timor J
Int J Biol Markers; 1999; 14(3):172-7. PubMed ID: 10569140
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
30. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer.
Safi F; Kuhns V; Beger HG
Int J Biol Markers; 1995; 10(2):100-6. PubMed ID: 7561233
[TBL] [Abstract][Full Text] [Related]
31. The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers.
Coban S; Ozkan H; Köklü S; Yüksel O; Koçkar MC; Akar T; Ormeci N
Can J Gastroenterol; 2006 Sep; 20(9):593-6. PubMed ID: 17001401
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
33. Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers.
Andriulli A; Gindro T; Piantino P; Farini R; Cavallini G; Piazzi L; Naccarato R; Dobrilla G; Verme G; Scuro LA
Digestion; 1986; 33(1):26-33. PubMed ID: 3940235
[TBL] [Abstract][Full Text] [Related]
34. Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study.
Guadagni F; Roselli M; Amato T; Cosimelli M; Mannella E; Perri P; Abbolito MR; Cavaliere R; Colcher D; Greiner JW
Cancer; 1991 Dec; 68(11):2443-50. PubMed ID: 1933781
[TBL] [Abstract][Full Text] [Related]
35. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L
Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620
[TBL] [Abstract][Full Text] [Related]
37. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
38. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
Staab HJ
Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
[No Abstract] [Full Text] [Related]
39. [CA72-4 and CEA in serum and peritoneal washing in gastric cancer].
Mandorwski S; Lourenço LG; Forones NM
Arq Gastroenterol; 2002; 39(1):17-21. PubMed ID: 12184160
[TBL] [Abstract][Full Text] [Related]
40. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.
Staab HJ; Brümmendorf T; Hornung A; Anderer FA; Kieninger G
Klin Wochenschr; 1985 Feb; 63(3):106-15. PubMed ID: 3856076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
